In contrast with cytotoxic therapy, the impact of hormonal therapy for advanced breast cancer in postmenopausal women is poorly documented. Two recent surveys of the impact of hormonal therapy in this patient group found that side-effects had an adverse impact on patients’ quality of life which needed to be taken into account when discussing treatment options. Patients were perceived to be more comfortable discussing treatment-related problems with nurses rather than doctors, who tended to underestimate the distress caused to patients by the side-effects of treatment. A need was identified for better lines of communication between patients and medical professionals, and for a simple, more widely applicable tool for assessment of side-effects. As a result of these findings, a simple checklist, Checklist for Patients on Endocrine Therapy (C-PET), has been developed to be completed by patients before a physician appointment, to form a basis for discussion. A pilot study has indicated that C-PET is easy and quick for patients to complete and aids communication between patients and healthcare professionals. C-PET has now been formally launched to nurses, oncologists, and other cancer physicians.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.